Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec 20;7(3):LMT07.
doi: 10.2217/lmt-2018-0014. eCollection 2018 Nov.

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies

Hugo Arasanz  1   2   1   2 , Miren Zuazo  1   1 , Ruth Vera  2   2 , Grazyna Kochan  1   1 , David Escors  1   3   1   3
Affiliations
Editorial

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies

Hugo Arasanz et al. Lung Cancer Manag. .
No abstract available

Keywords: B7-H1; NSCLC; PD-1; PD-L1; T lymphocyte; biomarker; immune checkpoint blockade.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The immunomodulation group is funded by Asociación Española Contra el Cáncer (AECC, PROYE16001ESCO); Instituto de Salud Carlos III, Spain (FIS project grant PI17/02119), a ‘Precipita’ Crowdfunding grant (FECYT). D Escors is funded by a Miguel Servet Fellowship (ISC III, CP12/03114, Spain); M Zuazo I is supported by a scholarship from Universidad Pública de Navarra; H Arasanz is supported by a scholarship from AECC. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

    1. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. - PubMed
    1. Horn L, Mansfiled AS, Szczęsna A, et al. IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 2018 Epub ahead of print. - PubMed
    1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 2016;375(19):1823–1833. - PubMed
    1. Champiat S, Ferrara R, Massard C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat. Rev. Clin. Oncol. 2018 Epub ahead of print. - PubMed
    1. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, Phase III trials (CheckMate 017 and CheckMate 057) J. Clin. Oncol. 2017;35(35):3924–3933. - PMC - PubMed

Publication types